New Triple-Threat treatment trial aims to keep aggressive lung cancer at bay
NCT ID NCT03830918
Summary
This trial is testing a combination of three drugs (niraparib, temozolomide, and atezolizumab) to see if they work better together to control advanced cancers, especially a type called extensive-stage small cell lung cancer. The study first finds a safe dose, then compares the three-drug combo to a single drug to see which keeps the cancer from growing longer. It is for people whose cancer has responded to initial chemotherapy but is not cured.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIB LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.